Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
DOCUMENT DATABASE

Acasti Pharma

acastipharma.com

2014-01-09-FDA-Clears-APOs-Investigational-New-Drug-Submission-to-Conduct-PK-Trial
2014-01-14-APO-Announces-Third-Quarter-Results
2014-02-07-APO-Announces-Closing-of-CAD2.15-Million-Private-Placement
2014-02-14-NTB-APO-Provide-Update-on-Patent-Litigations-with-Enzymotec
2014-04-28-NTB-APO-NBP-Announce-Resignation-of-CEO
2014-04-28-NTB-Enzymotec-Conclude-Final-Patent-Infringement-Settlement-License-Agreement
2014-05-01-APO-to-Present-at-Two-Scientific-Forums
2014-05-21-APO-Announces-Fourth-Quarter-and-Fiscal-Year-Results
2014-05-23-NTB-APO-NBP-Announce-Appointment-of-Interim-CEO
2014-05-30-NTb-APO-NBP-Announce-Litigation-Regarding-its-Former-CEO
2014-06-16-APO-Announces-Resignation-of-Chief-Financial-Officer
2014-06-20-APO-Reports-Results-of-Annual-and-Special-Meeting
2014-06-24-APO-Announces-Oral-Presentation-on-COLT-Study-Results-at-19th-World-Congress
2014-06-26-APO-Grants-of-Stock-Options
2014-07-09-APO-Completes-Phase-II-Double-Blind-TRIFECTA-and-Pharmacokinetic-Trials
2014-07-15-APO-Announces-First-Quarter-Results
2014-07-26-WorldCongress
2014-09-29-APO-Reports-Successful-CaPreR-Phase-II-TRIFECTA-Results
2014-09-30-APO-Announces-Positive-Top-Line-Pharmacokinetic-Results
2014-10-14-APO-Announces-Second-Quarter-Results
2014-10-20-Acasti-Announces-Grant-of-Stock-Options
2014-11-11-APO-Receives-NASDAQ-Notification-Regarding-Minimum-Bid-Requirements
2015-01-13-APO-Announces-Third-Quarter-Results
2015-03-02-APO-Receives-Full-Data-for-Phase-II-TRIFECTA-Trial
2015-03-23-USPTO-Issues-Positive-Decision-That-Triggers-Royalty-Payments-to-NTB
2015-03-25-APO-Granted-Composition-Use-Patent-in-China
2015-04-29-APO-Announces-Departure-of-Chief-Financial-Officer
2015-05-11-APO-Receives-Extension-to-Regain-Compliance-With-NASDAQ-Minimum-Bid-Price-Rule
2015-05-27-APO-Announces-Fourth-Quarter-and-Fiscal-Year-Results
2015-05-27-APO-Announces-New-Board-of-Director-Nominees-for-Election-at-Annual-Special-Meeting-of-Shareholders
2015-06-01-APO-Announces-Grant-of-Stock-Options
2015-07-13-APO-Announces-First-Quarter-Results
2015-08-05-Mario-Paradis-Appointed-CFO-of-NTB-and-APO
2015-08-19-APO-Announces-Grant-of-Stock-Options
2015-09-29-APO-Announces-1-for-10-Reverse-Stock-Split
2015-10-14-APO-Announces-Second-Quarter-Results
2015-12-01-APO-Granted-Composition-Use-Patent-in-Japan-Taiwan-and-Mexico
2015-12-16-APO-Provides-Update-on-CaPre�-Development-Pathway
2016-01-07-APO-NTB-Enter-Into-Transactional-Arrangement-Sign-Operational-Agreements
2016-01-12-APO-Announces-Third-Quarter-Results
2016-02-05-Acasti-Announces-Share-for-Debt
2016-03-01-APO-Announces-Management-Appointment-and-Changes-to-the-Board-of-Directors
2016-03-25-Nasdaq-Grants-APO-Cure-Period-to-Regain-Compliance-with-Audit-Committee-Membership-Requirements
2016-05-12-Jan-DAlvise-Appointed-President-CEO-of-APO
2016-05-25-APO-Announces-Fourth-Quarter-and-Fiscal-Year-Results
2016-05-30-APO-Announces-Grant-of-Stock-Options
2016-07-11-APO-Announces-First-Quarter-Results
2016-07-15-APO-Announces-the-Election-of-its-Directors-Change-of-Fiscal-Year-End-and-Other-Related-Matters-Passed-at-its-AGM
2016-09-14-APO-Reports-Positive-CaPre-Omega-3-Bridging-Study-Data
2017-Financial-Statements.-English
2017-YE-MDA.-English
2018-02-28-Acasti-Appoints-SAB_7March2017-final
Acasti_China-Partner-PR-FINAL-11.20.17
Acasti_China-Partner-Term-PR-FINAL-11.22.17
Acasti_FS_Q3-2018_2018-02-13_FINAL
Acasti_NLA-2017_v4_04MAY2017-1
Acasti_Press-Release_Financing_Closing_12.27.17_FINALFINAL
Acasti_Press-Release_Q2-FY18-Interest-Payment-in-Shares_2017-10-04
Acasti_Press-Release_Q2-FY18-Interest-Payment-in-Shares_FINAL-2017-12-21
Acasti_Press-Release_Q3-FY18-Interest-Payment-in-Shares_Final
Acasti_Press-Release_Q4-FY18-Interest-Payment-in-Shares_Final1
Acasti-Circular-2017-English
Acasti-Closing-of-Public-Offering-21Feb17-English
Acasti-Director-change-PR-180116_Final
Acasti-EOP2-PR-March-2017.FINAL_
Acasti-Final-Prospectus-English
Acasti-First-Patient-Enrolled-13March2018FINALFINAL
Acasti-FS-2017-06-30
Acasti-MDA_Q1-FY-18_08-09
Acasti-Mozaffarian-Press-Release.3November2017-FINAL
Acasti-NLA-PR-FINAL.11April2017
Acasti-NLA-PR-Follow-Up-Final-English
Acasti-Notice-of-Meeting-AGM-2017-English
Acasti-OKeefe-CFO-PR-FINAL_ENG
Acasti-Overnight-Marketed-Public-Offering-Canada-PR-FINAL
Acasti-Patent-Final
Acasti-Pharma-Reports-Third-Quarter-FY-2018-Financial-Results
Acasti-PR_Stock-Options_2017-06-14__FINAL
Acasti-PR_Stock-Options_2017-08-31_vFinal
Acasti-PR_Stock-Options_20170224_final
Acasti-PR_Stock-Options_Correction-FINAL
Acasti-PR-BOD-Don-Olds-FINAL-04.27.18
Acasti-PR-regarding-Over-Allotment-Exercise.22January2018
Acasti-Preliminary-Prospectus-PR-FINAL-ENG
Acasti-Presents-at-Biotech-Showcase.FINAL_
Acasti-Press-Release-Q1-FY18_08-14-17
Acasti-Press-Release-Q2-FY18_11.13.17_Final
Acasti-Press-Release-regarding-AGM-Results-August-15-2017
Acasti-Pricing-PR-Canada-FINAL
Acasti-Q3-FS-english
Acasti-Q3-MDA-english
Acasti-Q3-PR_English-Final
Acasti-Q217-Financial-Results-PR-FINAL-FINAL
Acasti-SEDAR-Report-re-Voting-Results-August-15-2017
Acasti-YE2017-Press-Release.-English
AcastiPharma_Wed_Yosemite-A_1100
Acastis-Upcoming-Presentations.-Final.-English-1
Acastis-Upcoming-Presentations.-Final.-English-2
ACST_MDA_Q3-FY-18_FINAL_2018-02-14
ACST-Announces-Proposed-Private-Placement-of-Convertible-Debentures-and-Amended-Proposed-Offering-of-Units
ACST-Ticker-Symbol-Change-TSXV_EN_final
Annual-Information-Form-2014
Annual-Information-Form-2015
API_FS-Q2-FY-18
API_MDA-Q2-FY-18
APWQ_SEDAR_Proxy_English-1
Financial-Statements-FY-Feb-28-2015-2014-2013
Financial-Statements-YE-Feb-28-2014-and-2013
Finanical-Statements-YE-Feb-29-2016-2015-2014
Form-20-F-2016
Form-of-Proxy-2014
Form-of-Proxy-2015
Form-of-Proxy-2016
Korea-Canada-patent-PR-22December2017
Management-Discussion-Analysis-YE-Feb-28-2014-2013
Management-Discussion-Analysis-YE-Feb-28-2015-2014-2013
Management-Discussion-Analysis-YE-Feb-29-2016-2015-2014
Management-Proxy-Circular-2014
Management-Proxy-Circular-2015
Management-Proxy-Circular-2016
March-and-June-2017-Interest-Payments_07-26-17.-FinalFINAL
Notice-of-Meeting-2014
Notice-of-Meeting-2015
Notice-of-Meeting-2016
presentation-20140501
Q1-2013-14-Financial-Statements
Q1-2013-14-MDA
Q1-2014-15-Financial-Statements
Q1-2014-15-MDA
Q1-2015-16-Financial-Statements
Q1-2015-16-MDA
Q1-2016-17-Financial-Statements
Q1-2016-17-MDA
Q2-2013-14-Financial-Statements
Q2-2013-14-MDA
Q2-2014-15-Financial-Statements
Q2-2014-15-MDA
Q2-2015-16-Financial-Statements
Q2-2015-16-MDA
Q2-2016-17-Financial-Statements
Q2-2016-17-MDA
Q3-2013-14-Financial-Statements
Q3-2013-14-MDA
Q3-2014-15-Financial-Statements
Q3-2014-15-MDA
Q3-2015-16-Financial-Statements
Q3-2015-16-MDA
Taiwan-patent-PR-Final
WCHD_-July-2017abstract-086_PK_saf_eff-Capre

error: Content is protected